{"id":"NCT01581593","sponsor":"Kedrion S.p.A.","briefTitle":"Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)","officialTitle":"Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects With Primary Immunodeficiency (PID).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11-12","primaryCompletion":"2014-08-27","completion":"2014-08-27","firstPosted":"2012-04-20","resultsPosted":"2021-02-16","lastUpdate":"2021-02-16"},"enrollment":45,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency","Agammaglobulinemia","Hypogammaglobulinemia","Antibody Deficiency"],"interventions":[{"type":"BIOLOGICAL","name":"Kedrion IVIG 10%","otherNames":[]}],"arms":[{"label":"Kedrion IVIG 10%","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether Kedrion IVIG 10% (an immunoglobulin solution) is effective in treating Primary Immunodeficiency (PID).","primaryOutcome":{"measure":"Incidence of Acute, Serious Bacterial Infections in the Total ITT Population.","timeFrame":"13 months","effectByArm":[{"arm":"Kedrion IVIG 10% 21 and 28 Days Infusion Schedule","deltaMin":0.04,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":1},"locations":{"siteCount":15,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":45},"commonTop":["Upper Respiratory Tract Infection","Headache","Investigations","Sinusitis","Pyrexia"]}}